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Abstract Although aldose reductase (AR) is a critical partic-
ipant in osmoregulation, and the metabolism of glucose and
aldehydes derived from lipid peroxidation, post-translational
mechanisms regulating its activity have not been identi¢ed. In
this paper, we report that stimulation of protein kinase C (PKC)
in several cell types induces phosphorylation of AR and trans-
location of the phosphorylated protein to the mitochondria. In
vitro, recombinant AR was directly phosphorylated by activated
PKC, suggesting that AR may be an in vivo PKC substrate.
Together, these observations reveal a novel link between PKC
activation and the regulation of glucose and aldehyde metabo-
lism.
% 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Aldose reductase (AR), a member of the aldo-keto reduc-
tase superfamily [1^3], catalyzes the reduction of a wide range
of aldehydes, including glucose [1]. Reduction of glucose by
AR generates sorbitol, which used for fructose synthesis, or as
an inert osmolyte in the renal medulla [4]. Increased sorbitol
generation and accumulation has also been linked to the de-
velopment of secondary diabetic complications [1,3], and in-
hibition of AR has been shown to prevent diabetic cataracts,
nephropathy, and neuropathy [1,3]. Recent structural and ki-
netic studies [5^7] indicate that aldehydes more hydrophobic
than glucose are preferred AR substrates. Because several of
these aldehydes are toxic and derived from lipid peroxidation
[8], it has been suggested that AR may have a protective anti-
oxidant function [9,10]. Consistent with this role, AR is upre-
gulated by oxidants such as H2O2 [11], lipid peroxidation-
derived aldehydes [12], and advanced glycosylation end prod-
ucts [13]. Nevertheless, the acute regulation of the enzyme by
post-translational modi¢cations has not been examined.
Members of the protein kinase C (PKC) family play a vari-
ety of regulatory roles in signaling events related to growth,
di¡erentiation, and cell death [14,15]. These enzymes are
stimulated by oxidative stress and mediate the generation of
reactive oxygen species. Multiple lines of circumstantial evi-
dence suggest an interrelationship between AR and the PKC.
Stimulation of AR during in£ammation or growth is preceded
by PKC activation, and both AR and PKCK are coordinately
up regulated in cells overexpressing GLUT1 [16]. Moreover,
PKCL-selective inhibitors prevent sorbitol accumulation [17],
and it has been suggested that the hyperglycemia-induced in-
crease in endothelial AR and PKC is mediated by common
signaling pathways activated by oxidative stress [18]. Addi-
tionally, it has been shown that AR is physically associated
with the PKCO signaling module in transgenic mice overex-
pressing PKCO in the heart [19]. Nonetheless, the relationship
between AR and PKC has not been directly investigated.
Herein, we report for the ¢rst time that AR is phosphorylated
upon stimulation of PKC in cells and in vitro, and that phos-
phorylation increases the association of AR with mitochon-
drial membranes.
2. Materials and methods
Bryostatin-1 (bryo-1) was a kind gift of G.R. Pettit (Arizona State
University, Tempe, AZ, USA). The REH, HL60, and COS-7 cells
were obtained from the ATCC (Rockville, MD, USA) and maintained
in RPMI 1640 containing 10% bovine calf serum at 37‡C in 5% CO2.
The murine IL-3-dependent cell line, NSF.N1H7 (H7) was a kind gift
of H. Scott Boswell. The vascular smooth muscle cells (VSMC) were
isolated from rat aorta and cultured as described before [20]. To mea-
sure phosphorylation, cells were serum-starved for 48 h and were in-
cubated with 0.5 mCi ml31 [32P]orthophosphoric acid for 4 or 6 h,
after which 1 WM okadaic acid was added to the medium. The cells
were incubated for an additional 5 min and then stimulated with PKC
agonists. After 10 or 30 min, the cells were frozen over dry ice, and
pelleted at 5000Ug for 5 min at 4‡C and resuspended in 0. 5 ml of the
lysis bu¡er containing 50 mM Tris^HCl, pH 7.4, 150 mM NaCl, 50
mM NaF, 0.5 mM NaVO3, 10 mM EDTA, 5 mM EGTA, 50 WM
leupeptin, 50 WM pepstatin, 1 mM PMSF, 50 nM okadaic acid, 1%
Nonidet P-40 and 1 mM iodoacetate. The cell extracts were centri-
fuged at 14 000Ug for 15 min, and the supernatant was recovered and
mixed with 0.2% sodium dodecyl sulfate (SDS). The AR protein was
immunoprecipitated as described previously [21,22] using polyclonal
antibodies raised against human recombinant AR in rabbits [12].
Samples were electrophoresed and Western blots were developed as
described before [21]. Two-dimensional electrophoresis (2DE) was
performed using immobilized pH gradient strips (IPG; Amersham
Pharmacia Biotech Inc., Piscataway, NJ, USA), rehydrated overnight
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with immunoprecipitant in rehydration bu¡er containing 8 M urea,
2% CHAPS, 0.01 M dithiothreitol (DTT), 2% ampholytes and bro-
mophenol blue. The strips were then focused with maximal 5000 V
and 80 mA at 17‡C for 24 h to reach 100 000 V h31. After focusing,
the samples were equilibrated with bu¡er containing 6 M urea, 130
mM DTT, 30% glycerol, 112 mM Tris base, 4% SDS, 0.002% bromo-
phenol blue and acetic acid, then with bu¡er containing 6 M urea, 135
mM iodoacetamide, 30% glycerol, 112 mM Tris base, 4% SDS,
0.002% bromophenol blue and acetic acid. The strips were loaded
onto pre-cast 10% homogeneous, 22U22 cm slab gels (Genomic So-
lutions Inc., Ann Arbor, MI, USA). The gels were stained by SYPRO
ruby stain (Bio-Rad Laboratory, Hercules, CA, USA). Time-of-£ight
mass spectrometry (MALDI-TOF MS), and peptide mass ¢nger-
printing (PMF) was performed after in-gel tryptic digestion and pro-
tein identi¢cation was performed by using PROFOUND (http://
129.85.19.192/profound_bin/WebProFound.exe) as described previ-
ously [23].
Subcellular fractions were obtained using previously published pro-
cedures [24]. The purity of the fractions was con¢rmed by assessing
localization of fraction-speci¢c proteins, including prohibitin (heavy
membrane, HM) and CPP32 (cytosolic). The cell surface transferrin
receptor (TrR) was localized exclusively to the light membrane frac-
tion (LM; data not shown). The AR protein was puri¢ed and assayed
for activity as described previously [6,7]. Recombinant AR was phos-
phorylated by the rat brain pan-PKC or human PKC isoforms (Pan-
vera, Madison, WI, USA) at 30‡C in 50 Wl reaction mixtures contain-
ing 1 Wg ml31 AR, 50 mM Tris (pH 7.2), 50 mM NaCl, 1% glycerol,
10 mM MgCl2, 2 mM DTT, 2 mM CaCl2, 100 WM ATP, 1 WCi
[Q-32P]ATP, 40 Wg ml31 phosphatidylserine, 10 nM bryo-1, and 0.4
Wg PKC. The proteins were separated on SDS^PAGE and 32P incor-
poration was detected by autoradiography.
3. Results and discussion
To examine the e¡ect of PKC on AR, we measured the
incorporation of 32P into the AR protein in three di¡erent
types of cells stimulated by PKC agonists. The REH, the
HL-60, and VSMC cells were metabolically labeled with 32P
and incubated with 10 nM bryo-1, which is a potent stimula-
tor of the PKC family of kinases [24]. After 15 min of incu-
bation, the cells were lysed and AR was immunoprecipated
from the extract using anti-AR antibodies. The immunopreci-
pitates were separated on SDS^PAGE and AR was identi¢ed
by Western analysis using anti-AR antibody and 32P incorpo-
ration was visualized by autoradiography. In all cases, stim-
ulation with bryo-1 induced 32P incorporation into AR (Fig.
1A), indicating that stimulation of PKC leads to the phos-
Fig. 1. Stimulation of PKC phosphorylates AR in REH, HL-60,
smooth muscle, and COS-7 cells. The cells were labeled with
[32P]orthophosphoric acid for 1 h and then stimulated with either
the vehicle or 10 nM bryo-1 for 15 min. Immunoprecipitated AR
was separated on SDS^PAGE, and after autoradiography (panel A,
top) the same ¢lter was reprobed with AR-antisera for developing
Western blots (panel A, bottom). Precipitates of the cell lysates with
pre-immune serum were negative for AR. Panel B shows the auto-
radiogram and Western Blot of COS-7 cell AR labeled with
[32P]orthophosphoric acid and stimulated with 100 nM PMA for 30
min. The cells were lysed and AR was immunoprecipitated, and
then subjected to 2D electrophoresis, Western blot analysis, and
autoradiography.
Fig. 2. Stimulation of PKC selectively enriches the mitochondrial
membrane fraction with AR. The REH or the NSF.N1H7 cells
(107) were stimulated with 10 nM byrostatin-1, and the following
fractions were isolated: HM, LM, and cytoplasm (Cyto) and sepa-
rated on SDS^PAGE. The Western blots are shown in panel A.
Panel B shows a graphical representation of the densitometric analy-
sis of three independent experiments.
Fig. 3. Preferential phosphorylation of AR associated with the mito-
chondrial fraction. The REH cells (2U107) were labeled with [32P]
and stimulated with 10 nM bryo-1. Following subcellular fractiona-
tion, 50 Wg protein from each fraction was separated on SDS^
PAGE. After autoradiography, the same membrane was subjected
to Western blotting with AR-antisera. The autoradiographs and the
extent of radioactivity incorporated is shown in panel A. Panel B
shows Western blots of AR in the HM and cytosolic (Cyto) frac-
tion. Bars in panels A and B are the mean values obtained from
three independent experiments.
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phorylation of AR. Similar results were obtained with the
three cell types examined, suggesting that phosphorylation
of AR upon stimulation of PKC may be a phenomenon com-
mon to cells of diverse origins. Incubation of VSMC with 100
nM PMA for 10 min also led to the phosphorylation of AR
(data not shown), indicating that the phosphorylation of AR
is independent of the nature of the agonist used to activate
PKC.
To determine whether the phosphorylated band was identi-
cal to AR protein, the 32P-labeled COS-7 cells were stimulated
with PMA and then subjected to 2DE. AR was identi¢ed by
Western analysis as a 36 kDa protein focusing between 6.9
and 7.8 pH units (Fig. 1B), which corresponded to the posi-
tion of the protein spot (in pI and molecular weight) detected
by autoradiography. To further con¢rm the identity of this
protein, immunoprecipitates from PMA-stimulated VSMC
was separated by 2DE and the corresponding spot was excised
and subjected to in-gel tryptic digestion followed by MALDI-
TOF MS and PMF. Peptide masses obtained from MALDI-
TOF MS con¢rmed the identity of the immunoprecipitated
protein as AR.
In unstimulated cells, AR was localized primarily to the
cytosolic fraction, and 6 10% of this protein was associated
with the LM or HM fractions. However, upon bryo-1 stimu-
lation, AR in the cytosolic and the LM fraction was de-
creased, whereas AR associated with HM was increased
more than three-fold (Fig. 2). Similar changes in intracellular
distribution of AR were observed in NSF.N1H7 cells. As
shown in Fig. 2, in unstimulated NSF.N1H7 cells only trace
levels of AR were associated with the HM fraction. However,
stimulation of these cells by bryo-1 led to an increase in AR
associated with this fraction.
To examine whether the phosphorylation of AR upon PKC
activation displays site-speci¢city, metabolically labeled REH
cells were stimulated with bryo-1 for 15 min, after which the
cells were harvested and their subcellular fractions were pre-
Fig. 4. Activated PKC isoforms phosphorylate AR. Recombinant AR was incubated with the indicated PKC isoforms and the reaction mixture
was separated on SDS^PAGE and the extent of phosphorylation was measured by autoradiography. Panel A shows autophosphorylated pan-
PKC and panel B shows the autophosphorylated PKCK, LII, and O. The presence or absence of phosphatidylserine and Ca2þ in the phosphory-
lation mixture is also indicated. The PKCO phosphorylation did not require either Ca2þ or phosphatidylserine, although the autophosphoryla-
tion of pan-PKC was greatly reduced in absence of phosphatidylserine (panel A, lane 3), but was less a¡ected by the nominal absence of Ca2þ
in the incubation mixture (lane 2). Panel C shows phosphorylation of AR by activated pan-PKC in the presence (lane 1) or the absence (lane
3) of phosphatidylserine or the absence of Ca2þ (lane 2). Lane 4 of panel C shows pan-PKC-induced phosphorylation of denatured AR (heated
at 70‡C for 15 min). Panel D shows the phosphorylation of AR when incubated with K, LII, and O, in lanes 1^3, respectively. Panel E shows
the extent of 32P incorporation into AR protein in the presence of indicated PKC isoforms.
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pared. As shown in Fig. 3, the extent of AR phosphorylation
was signi¢cantly higher in the HM fraction, indicating that
stimulation of PKC not only leads to redistribution of AR,
but also enhances the fraction of phosphorylated AR associ-
ated with the mitochondria.
To examine whether AR is a direct substrate of PKC, re-
combinant AR was incubated in the PKC assay bu¡er con-
taining pan-PKC. After varying durations of incubation, the
reaction mixture was separated on SDS^PAGE, transferred to
a nitrocellulose membrane, and the phosphorylation of AR
and PKC was visualized by autoradiography. As shown in
Fig. 4, AR was intensely phosphorylated in the complete re-
action mixture containing calcium, phosphatidylserine and
pan-PKC. In the absence of PKC, no 32P was incorporated
into AR. For optimal phosphorylation, the native conforma-
tion of AR appeared to be necessary, because when denatured
AR (prepared by heating the protein for 15 min at 70‡C) was
incubated with the pan-PKC, the extent of phosphorylation
was diminished (Fig. 4C, lane 4). The phosphorylation of AR
also required phosphatidylserine and calcium. Although omis-
sion of phosphatidylserine from the incubation mixture com-
pletely prevented phosphorylation, the presence of calcium
was less critical (Fig. 4C). Because pan-PKC contains a mix-
ture of PKC isozymes, it is likely that some of the non-classic
PKC isoforms may have phosphorylated AR in the absence of
calcium. Regardless, these observations clearly show that AR
is phosphorylated by PKC and that this phosphorylation de-
pends upon phosphatidylserine and calcium.
To establish the relative speci¢city of PKC isoforms for
AR, AR was incubated with pure, recombinant human
PKC isoforms. Among these isozymes, PKCK appeared to
be most e⁄cient in phosphorylating AR, whereas, less intense
phosphorylation was observed with PKCLII and PKCO. The
relative speci¢city of other PKC isoforms is shown in Fig. 4E.
These values are expressed as the total cpm incorporated in
AR when incubated with equimolar concentrations of the
PKC isoforms. When normalized to the extent of incorpora-
tion induced by PKCK, the relative e⁄ciencies of the other
PKC isoforms with AR were: (K=1) LI = 0.54, LII = 0.71,
O=0.42, N=0.83 and j=0.28. Moreover, with activated
PKCK alone, AR was rapidly phosphorylated and the extent
of phosphorylation was maximal in 30 min and half-maximal
phosphorylation was observed in 6 2 min. At maximal phos-
phorylation, 0.92^1.01 mol of inorganic phosphate were in-
corporated per mol of AR.
Collectively, these results suggest that phosphorylation of
AR by PKC may be a phenomenon general to several cell
types. At least for the cells examined, rapid and robust phos-
phorylation of AR was observed, which in the REH cells was
associated with the migration of AR to the mitochondria.
Although AR is considered a cytosolic protein, our data
(Fig. 2) show that even in the non-stimulated cells, detectable
levels of AR were associated with LM and HM fractions, and
that the association of AR with the HM fraction was in-
creased upon PKC stimulation. This is in agreement with
the observation that brief episodes of ischemia lead to a
PKC-dependent increase in the association of AR with the
particulate fraction in the heart [25], and suggest that AR
associates with cell membranes either directly or as a part of
a signaling complex as described for the PKCO signaling mod-
ule [19].
The physiological implications of PKC-dependent phos-
phorylation and translocation of AR remain unclear. How-
ever, given the role of AR in the metabolism of lipid-derived
aldehydes, we speculate that AR may be required for the
detoxi¢cation of aldehydes generated during the breakdown
of membrane lipids, which is a necessary step in PKC activa-
tion. Thus, AR may be essential for removing lipid peroxida-
tion products from the lipid microdomains that associate
with, and are essential for, PKC activation. Additionally,
phosphorylation by PKC may be a mechanism for regulating
glucose metabolism or fructose synthesis. Although further
experiments are required to test this view, our current results
suggest that AR may be one of the downstream targets and
ende-¡ectors of PKC signaling. These data reveal a novel and
unanticipated link between PKC and aldehyde or glucose me-
tabolism and may be of signi¢cance in understanding the
PKC-induced changes in the intermediary metabolism of cells
stimulated by growth factors, mitogens, or cytokines.
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